Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Price Target at $46.43

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been given an average recommendation of “Buy” by the ten brokerages that are covering the firm, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $46.43.

A number of equities research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Oppenheimer boosted their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Finally, TD Cowen initiated coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating for the company.

Dianthus Therapeutics Trading Down 0.5 %

Shares of NASDAQ DNTH opened at $21.10 on Tuesday. The business has a 50-day moving average of $23.11 and a 200-day moving average of $26.14. The firm has a market capitalization of $624.56 million, a price-to-earnings ratio of -8.44 and a beta of 1.74. Dianthus Therapeutics has a 12 month low of $17.41 and a 12 month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The company had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. On average, analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in shares of Dianthus Therapeutics in the third quarter worth about $556,000. Barclays PLC grew its position in shares of Dianthus Therapeutics by 390.5% in the 3rd quarter. Barclays PLC now owns 41,684 shares of the company’s stock worth $1,141,000 after buying an additional 33,185 shares during the last quarter. HighVista Strategies LLC purchased a new position in shares of Dianthus Therapeutics during the third quarter valued at approximately $542,000. State Street Corp raised its holdings in shares of Dianthus Therapeutics by 101.4% during the third quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after acquiring an additional 413,425 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Dianthus Therapeutics by 142.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after acquiring an additional 97,362 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.